Katherine N Weilbaecher MD

Associate Professor, Internal Medicine, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Weilbaecher is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weilbaecher's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
Stanford University School of MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1993 - Present
MO State Medical License 2000 - 2027
MA State Medical License 1994 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2016-2017
Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
TERMINATED
PHASE2
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
RECRUITING
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
WITHDRAWN
PHASE2

Publications & Presentations

PubMed

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.
Xinming Su, Takayuki Kobayashi, Jingyu Xiang, Yalin Xu, Ayesha N Shajahan-Haq
Journal of Bone Oncology. 2026-06-01
Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways.
Christopher Egbulefu, Kvar Black, Xinming Su, Partha Karmakar, LeMoyne Habimana-Griffin
Communications Biology. 2026-01-19
7 citations
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.
Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher, Rama Suresh, Lindsay L Peterson
Clinical Cancer Research. 2025-06-03

Journal Articles

Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss
Katherine Weilbaecher, MD, Clinical Cancer Research
The β3‐Integrin Endothelial Adhesome Regulates Microtubule‐Dependent Cell Migration
Katherine Weilbaecher, MD, Molecular Systems Biology

Press Mentions

WashU Professor on the Importance of Breast Cancer ScreeningsOctober 23rd, 2024
Capitol Dome to Be Lit Pink to Honor Breast Cancer PatientsOctober 18th, 2018

Grant Support

Mechanism of acid signaling in bone organ metastases on tumor and myeloid cell evolution towards immune suppression and tumor progressionWASHINGTON UNIVERSITY2025–2030
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPYWASHINGTON UNIVERSITY2018–2024
Next Generation Approaches To Breast Cancer Using Image Guided Drug DeliveryNational Cancer Institute2011–2012
Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2003–2012
Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2009